Tau Braun: Clots Through the Copper-Zinc Model
Tau Braun, Chief Executive Officer at BioChem Engineering LLC, shared a post on X:
“Clots Through the Copper-Zinc Model.
Bottom line: copper deficiency damages blood vessel walls, raises oxidative stress, and weakens immune defense against fungi. Together, those damaged walls and fungal toxins create the conditions for clots to form and travel to the lungs.
Copper and zinc power the enzymes that keep vessel walls intact and oxidative stress in check, so when either metal runs low, iron’s radical chemistry and fungal toxins can drive clotting.
The standard view is that clots form when blood flow slows, vessel walls are injured, or the blood becomes hypercoagulable, with deep vein thrombi able to break free and lodge in the pulmonary arteries as pulmonary embolism.
Starting copper deficient lowers lysyl oxidase, the enzyme that cross-links collagen and elastin in vessel walls. Fragile walls develop micro-tears that expose subendothelial collagen, triggering platelet adhesion and the coagulation cascade.
Copper is also a cofactor for superoxide dismutase, so deficiency raises oxidative stress that damages the endothelium directly.
The vessel loses its anticoagulant surface, nitric oxide drops, and the wall shifts pro-thrombotic. Copper deficiency further impairs iron metabolism, causing anemia, and can alter platelet count and function.
Zinc deficiency compounds the problem because zinc supports endothelial repair enzymes and helps regulate platelet reactivity, so a low zinc state leaves micro-injuries unrepaired longer and platelets more easily activated.
On amyloid, SOD1 needs copper to neutralize superoxide, so low copper lets reactive oxygen species accumulate and oxidize proteins into misfolded seeds. Amyloid-beta binds copper, and in copper-poor conditions that binding turns pro-aggregative, accelerating fibril deposition in vessel walls.
Fungal involvement adds another layer. Fungi like Candida produce amyloidogenic proteins and secrete candidalysin, a pore-forming toxin that punches holes in endothelial cells, creating exactly the kind of micro-injury that invites both clotting and amyloid seeding.
Some fungal cell wall components cross-react with immune receptors that also recognize amyloid aggregates, potentially amplifying the cascade.
Copper normally suppresses fungal growth, so deficiency removes that brake and lets fungal burden rise, feeding both the clot and amyloid pathways simultaneously.
The whole picture is one of convergence: fragile vessels, oxidative damage, clotting tendency, amyloid deposition, and unchecked fungal overgrowth, all pointing at the pulmonary circulation as a high-risk site.
It is hard to treat because standard anticoagulation stops new clot formation and existing clots can be dissolved or removed, yet none of those approaches rebuild vessel wall integrity, restore the copper zinc antioxidant shield, clear trapped iron, or reduce the fungal burden that continues to injure the endothelium.
Anticoagulants are standard care and reduce embolization risk; however, long-term use carries bleeding risk and does not address the underlying metal, oxidative, or microbial drivers that keep the vessel wall pro-thrombotic.
The recommendation is to replete copper and zinc gently toward balance, support glutathione and GPX4 with NAC and selenium, address iron dysregulation through diet or supervised approaches when ferritin is high, and consider antifungal or biofilm-disrupting measures when fungal overgrowth is suspected, while using standard anticoagulation when clinically indicated.
Ratio: copper to zinc near one to one means the vessel defense is intact; a skew shows which metal to restore first. Tests: serum copper, serum zinc, ceruloplasmin, ferritin, transferrin saturation, and ideally free copper calculated from those values.
Disclaimer: informational purposes only, not medical advice.”
Stay updated with Hemostasis Today.
-
Oct 21, 2026, 09:55Cristina Figueroa Villalba: Celebrating Excellence in Transfusion Medicine
-
Oct 21, 2026, 09:43Ahmad Gharehbaghian: How Can Blood Supplies Be Sustained During a Crisis?
-
Oct 21, 2026, 09:30Adrián Dante De Angelis: Research That Opens New Possibilities for Recurrent iTTP
-
Oct 21, 2026, 09:13Jarod Horobin: Blood 2026 – Connecting Science and People
-
Oct 21, 2026, 08:35Raeeda Gheewala: VTE in Athletes – Risks Beyond the Playing Field
-
Oct 21, 2026, 08:29Andreas Kronbichler: The Changing Landscape of CV Risk in ANCA-Associated Vasculitis
-
Oct 21, 2026, 08:21Pham Quy: Taking Stroke Awareness Beyond Hospitals and Into the Community
-
Oct 21, 2026, 07:15Mahmoud Saad: Successful Mechanical Thrombectomy for Right Atrial Thrombosis
-
Oct 21, 2026, 06:55Hunain Shahbaz: Extended Dual Antiplatelet Therapy Beyond 12 Months After Drug-Eluting Stent Implantation